On Dec 03, major Wall Street analysts update their ratings for $Revolution Medicines (RVMD.US)$, with price targets ranging from $68 to $80.
J.P. Morgan analyst Eric Joseph maintains with a buy rating, and adjusts the target price from $63 to $71.
BofA Securities analyst Alec Stranahan maintains with a buy rating, and sets the target price at $80.
Needham analyst Ami Fadia maintains with a buy rating, and maintains the target price at $68.
Stifel analyst Benjamin Burnett maintains with a buy rating, and adjusts the target price from $70 to $80.
Furthermore, according to the comprehensive report, the opinions of $Revolution Medicines (RVMD.US)$'s main analysts recently are as follows:
Following a recent update on data across the RAS(ON) pipeline, analysts have revised their model to accommodate heightened success prospects, particularly in the second-line and first-line NSCLC treatments with RMC-6236. This adjustment aligns with positive developments in Phase 1 evaluations, which suggest a reduction in risk as the company advances towards pivotal Phase 3 trials in 2L NSCLC, slated to start in Q1, alongside anticipated trials in a 1L setting employing doublet/triplet regimens.
The raised evaluation of Revolution Medicines' shares is based on improved success assumption for its treatments in second-line non-small cell lung cancer. This follows the company's update on its clinical data concerning the RAS inhibitor pipeline, which has been assessed as generally positive, helping to further mitigate the risks associated with its clinical development strategies in PDAC, NSCLC, and CRC.
The recent study outcomes indicated that the expected dose of 300mg RMC-6236 wasn't as effective or tolerable when used with pembro, contributing to a less robust stock response. However, results from the 200mg dose demonstrated considerable effectiveness, suggesting an additive effect alongside pembro, which could potentially exceed the standard of care in first-line NSCLC treatments. The combination's safety profile concerning liver toxicity appears favorable, though the limited duration of the follow-up could raise concerns. Despite the necessity to reduce dosages in NSCLC contexts, the observed efficacy supports the pursuit of significant opportunities in first-line NSCLC treatments. Market sensitivity to deviations from expected results has heightened investor caution.
Here are the latest investment ratings and price targets for $Revolution Medicines (RVMD.US)$ from 4 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
